Hemoptysis

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
  • Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

Intuitive and Siemens Healthineers enhance scanning integration for Ion Endoluminal procedures

Retrieved on: 
Thursday, June 30, 2022

This new imaging integration could help improve the accuracy of biopsy procedures, a key step in how lung cancer gets diagnosed.

Key Points: 
  • This new imaging integration could help improve the accuracy of biopsy procedures, a key step in how lung cancer gets diagnosed.
  • The integration enhances a physicians ability to provide minimally invasive lung biopsy with the Ion system, which can give patients answers sooner.
  • With the Siemens Healthineers integration we are raising that bar further by enabling our physicians to even more accurately and repeatably biopsy small lesions deep within the lung.
  • Procedures using the Ion endoluminal system may be associated with longer procedure and/or longer anesthesia time.

Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022

Retrieved on: 
Wednesday, June 1, 2022

Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.

Key Points: 
  • Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.
  • As low as 2.5 g/mL pravibismane reduces intracellular M. avium 2285R (MDR) and M. abscessus 1153 (MDR) burden, superior to 20 g/mL rifampin and amikacin control drugs, respectively.
  • With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism.
  • Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection-relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA.

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, March 14, 2022

COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.

Key Points: 
  • COSMIC-312 is a global, multicenter, randomized, controlled phase 3 trial that enrolled 837 patients at 281 study centers globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX is not indicated as a treatment for previously untreated advanced HCC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma

Retrieved on: 
Wednesday, January 5, 2022

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated for metastatic RCC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
  • Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

2021 Insights on Small Cell Lung Cancer - 10-year Epidemiological Forecast - ResearchAndMarkets.com

Retrieved on: 
Monday, November 15, 2021

The "Small Cell Lung Cancer - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Small Cell Lung Cancer - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • SCLC is an aggressive form of lung cancer where approximately 60-70% of patients already have distant metastasis at presentation.
  • Small Cell Lung Cancer (SCLC) Epidemiology Report provides an overview of the risk factors and global trends of SCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • 2 Small Cell Lung Cancer: Executive Summary

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, November 9, 2021

In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.

Key Points: 
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX is not indicated as a treatment for metastatic NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.

PRECIsE Clinical Study Preliminary Results Favorable for Intuitive’s Ion Endoluminal System for Peripheral Nodule Lung Biopsy

Retrieved on: 
Monday, October 18, 2021

The similarity between yield rates for both smaller and larger nodules biopsied with Ion is a favorable result for clinicians seeking to sample smaller nodules.

Key Points: 
  • The similarity between yield rates for both smaller and larger nodules biopsied with Ion is a favorable result for clinicians seeking to sample smaller nodules.
  • A strong safety profile: the Ion system had no serious adverse events reported in this subset of patients in the study, and no pneumothorax events requiring a chest tube.
  • These are encouraging results on the potential for this technology to help safely biopsy small lung nodules.
  • The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy.

Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting

Retrieved on: 
Wednesday, September 8, 2021

The trial explored the effect of CMS I-neb on the frequency of pulmonary exacerbations in NCFB patients chronically infected with P. aeruginosa.

Key Points: 
  • The trial explored the effect of CMS I-neb on the frequency of pulmonary exacerbations in NCFB patients chronically infected with P. aeruginosa.
  • A total of 377 patients were randomized, 177 to CMS I-neb and 200 to placebo.
  • The annual rate of exacerbations was significantly lower in patients receiving CMS I-neb vs placebo (0.58 per patient per year vs 0.95, rate ratio (RR) 0.61 95% CI 0.46-0.82, p=0.00101).
  • These results are encouraging for patients as there is currently no approved drug treatment for this indication.